Skip to content

Released May 14, 2019, after the close

10-Q filed May 15, 2019, 45 days after period end · 0001564590-19-019236

Q1 2019 · 10-Q
Revenue$8.63M+49.0% vs Q1 2018−54.8% vs Q4 2018
Net Income-$14.25MN/M vs Q1 2018N/M vs Q4 2018
EPS Diluted-$0.62N/M vs Q1 2018N/M vs Q4 2018
Operating Income-$14,266,000N/M
Operating Cash Flow-$20,145,000N/M
Free Cash Flowderived-$20,421,000N/M
Margins · derived
Operating margin-165.3%+36.7 pt vs Q1 2018
Net margin-165.1%+42.8 pt vs Q1 2018

What the release said

The release

Same quarter

MetricQ1 2019Q1 2018Q1 2017
Revenue$8.63M$5.79M$14.85M
Net Income-$14.25M-$12.05M-$1.11M
EPS Diluted-$0.62-$25.76-$2.55

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR